Late effects of treatment for Hodgkin lymphoma

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 4, Issue 3, 2006, Pages 249-257

  Friedman, Debra L ^a,c   Constine, Louis S ^b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^c Fred Hutchinson Cancer Research Center   (United States)

Author keywords

Cancer survivors; Hodgkin lymphoma; Late effects; Long term toxicity

Indexed keywords

ALKYLATING AGENT; ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; BLEOMYCIN; BUSULFAN; CARMUSTINE; CHLORAMBUCIL; CHLORMETHINE; CYCLOPHOSPHAMIDE; CYTARABINE; DACARBAZINE; DOXORUBICIN; LOMUSTINE; PREDNISONE; PROCARBAZINE; VINCRISTINE;

AMENORRHEA; AUTOLOGOUS STEM CELL TRANSPLANTATION; AZOOSPERMIA; CANCER MORTALITY; CANCER RECURRENCE; CANCER RELAPSE; CANCER RISK; CANCER SURVIVAL; CANCER SURVIVOR; CARDIOMYOPATHY; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CHILDHOOD CANCER; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DISEASE FREE SURVIVAL; DISEASE PREDISPOSITION; ENDOCRINE DISEASE; GOITER; HEART DISEASE; HEART FAILURE; HEART MUSCLE FIBROSIS; HEMATOLOGIC MALIGNANCY; HODGKIN DISEASE; HUMAN; HYPOTHYROIDISM; INTERSTITIAL PNEUMONIA; IRRADIATION; LUNG FIBROSIS; LUNG TOXICITY; MALE INFERTILITY; MALIGNANT NEOPLASTIC DISEASE; MENSTRUAL IRREGULARITY; MULTIMODALITY CANCER THERAPY; MYOPATHY; PERICARDIAL DISEASE; PERICARDITIS; RADIATION DOSE; REVIEW; RISK ASSESSMENT; SOCIAL PSYCHOLOGY; SOLID TUMOR; SPERMATOGENESIS; SPLENECTOMY; THYROID DISEASE; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; GENERAL ASPECTS OF DISEASE; INFERTILITY; LUNG DISEASE; MENTAL DISEASE; NEUROLOGIC DISEASE; RADIOTHERAPY; SECOND CANCER;

ANTINEOPLASTIC AGENTS; CARDIOVASCULAR DISEASES; DISEASE; HODGKIN DISEASE; HUMANS; INFERTILITY; LUNG DISEASES; MENTAL DISORDERS; NEOPLASMS, SECOND PRIMARY; NERVOUS SYSTEM DISEASES; RADIOTHERAPY;

EID: 33645949736     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2006.0024     Document Type: Review

References (106)

1. Reis LAG, Eisner MP, Hankey BF, et al. SEER Cancer Statistics Review, 1975-2002. National Cancer Institute. Bethesda, MD. Accessed 01/10/06. Available at: http://seer.cancer.gov/csr/1975_2002/.
2. Mauch P, Ng A, Aleman B, et al. Report from the Rockefeller Foundation Sponsored International Workshop on reducing mortality and improving quality of life in long-term survivors of Hodgkin's disease: July 9-16, 2003, Bellagio, Italy. Eur J Haematol Suppl 2005;66:68-76.
3. Neglia JP, Friedman DL, Yasui Y, et al. Second malignant neoplasms in five-year survivors of childhood cancer: childhood cancer survivor study. J Natl Cancer Inst 2001;93:618-629.
4. Metayer C, Lynch CF, Clarke EA, et al. Second cancers among long-term survivors of Hodgkin's disease diagnosed in childhood and adolescence. J Clin Oncol 2000;18:2435-2443.
5. Hill DA, Gilbert E, Dores GM, et al. Breast cancer risk following radiotherapy for Hodgkin lymphoma: modification by other risk factors. Blood 2005;106:3358-3365.
6. Swerdlow AJ, Barber JA, Hudson GV, et al. Risk of second malignancy after Hodgkin's disease in a collaborative British cohort: the relation to age at treatment. J Clin Oncol 2000;18:498-509.
7. Travis LB, Hill D, Dores GM, et al. Cumulative absolute breast cancer risk for young women treated for Hodgkin lymphoma. J Natl Cancer Inst 2005;97:1428-1437.
8. Dores GM, Metayer C, Curtis RE, et al. Second malignant neoplasms among long-term survivors of Hodgkin's disease: a population-based evaluation over 25 years. J Clin Oncol 2002;20:3484-3494.
9. van Leeuwen FE, Klokman WJ, Veer MB, et al. Long-term risk of second malignancy in survivors of Hodgkin's disease treated during adolescence or young adulthood. J Clin Oncol 2000;18:487-497.
10. Bhatia S, Yasui Y, Robison LL, et al. High risk of subsequent neoplasms continues with extended follow-up of childhood Hodgkin's disease: report from the Late Effects Study Group. J Clin Oncol 2003;21:4386-4394.
11. Wolden SL, Lamborn KR, Cleary SF, et al. Second cancers following pediatric Hodgkin's disease. J Clin Oncol 1998;16:536-544.
12. van Leeuwen FE, Klokman WJ, Stovall M, et al. Roles of radiation dose, chemotherapy, and hormonal factors in breast cancer following Hodgkin's disease. J Natl Cancer Inst 2003;95:971-980.
13. Travis LB, Hill DA, Dores GM, et al. Breast cancer following radiotherapy and chemotherapy among young women with Hodgkin disease. JAMA 2003;290:465-475.
14. Travis LB, Gospodarowicz M, Curtis RE, et al. Lung cancer following chemotherapy and radiotherapy for Hodgkin's disease. J Natl Cancer Inst 2002;94:182-192.
15. Forrest DL, Hogge DE, Nevill TJ, et al. High-dose therapy and autologous hematopoietic stem-cell transplantation does not increase the risk of second neoplasms for patients with Hodgkin's lymphoma: a comparison of conventional therapy alone versus conventional therapy followed by autologous hematopoietic stem-cell transplantation. J Clin Oncol 2005;23:7994-8002.
16. Metayer C, Curtis RE, Vose J, et al. Myelodysplastic syndrome and acute myeloid leukemia after autotransplantation for lymphoma: a multicenter case-control study. Blood 2003;101:2015-2023.
17. Hosing C, Munsell M, Yazji S, et al. Risk of therapy-related myelodysplastic syndrome/acute leukemia following high-dose therapy and autologous bone marrow transplantation for non-Hodgkin's lymphoma. Ann Oncol 2002;13:450-459.
18. Krishnan A, Bhatia S, Slovak ML, et al. Predictors of therapy-related leukemia and myelodysplasia following autologous transplantation for lymphoma: an assessment of risk factors. Blood 2000;95:1588-1593.
19. Andre M, Henry-Amar M, Biaise D, et al. Treatment-related deaths and second cancer risk after autologous stem-cell transplantation for Hodgkin's disease. Blood 1998;92:1933-1940.
20. Adams MJ, Lipshultz SE, Schwartz C, et al. Radiation-associated cardiovascular disease: manifestations and management. Semin Radiat Oncol 2003;13:346-356.
21. Adams MJ, Lipsitz SR, Colan SD, et al. Cardiovascular status in long-term survivors of Hodgkin's disease treated with chest radiotherapy. J Clin Oncol 2004;22:3139-3148.
22. Fajardo LF, Eltringham JR, Steward JR. Combined cardiotoxicity of adriamycin and x-radiation. Lab Invest 1976;34:86-96.
23. Hancock SL, Donaldson SS, Hoppe RT. Cardiac disease following treatment of Hodgkin's disease in children and adolescents. J Clin Oncol 1993;11:1208-1215.
24. King V, Constine LS, Clark D, et al. Symptomatic coronary artery disease after mantle irradiation for Hodgkin's disease. Int J Radiat Oncol Biol Phys 1996;36:881-889.
25. Kremer LC, Caron HN. Anthracycline cardiotoxicity in children. N Engl J Med 2004;351:120-121.
26. Kremer LC, van Dalen EC, Offringa M, et al. Anthracycline-induced clinical heart failure in a cohort of 607 children: long-term follow-up study. J Clin Oncol 2001;19:191-196.
27. Pein F, Sakiroglu O, Dahan M, et al. Cardiac abnormalities 15 years and more after adriamycin therapy in 229 childhood survivors of a solid tumour at the Institut Gustave Roussy. Br J Cancer 2004;91:37-44.
28. Hull MC, Morris CG, Pepine CJ, Mendenhall NP. Valvular dysfunction and carotid, subclavian, and coronary artery disease in survivors of Hodgkin lymphoma treated with radiation therapy. JAMA 2003;290:2831-2837.
29. Heidenreich PA, Hancock SL, Lee BK, et al. Asymptomatic cardiac disease following mediastinal irradiation. J Am Coll Cardiol 2003;42:743-749.
30. Heidenreich PA, Hancock SL, Vagelos RH, et al. Diastolic dysfunction after mediastinal irradiation. Am Heart J 2005;150:977-982.
31. Mertens AC, Yasui Y, Neglia JP, et al. Late mortality experience in five-year survivors of childhood and adolescent cancer: the Childhood Cancer Survivor Study. [see comments]. J Clin Oncol 2001;19:3163-3172.
32. Moller TR, Garwicz S, Barlow L, et al. Decreasing late mortality among five-year survivors of cancer in childhood and adolescence: a population-based study in the Nordic countries. J Clin Oncol 2001;19:3173-3181.
33. Hoppe RT. Hodgkin's disease: complications of therapy and excess mortality. Ann Oncol 1997;8(suppl 1):115-118.
34. Hancock SL, Hoppe RT. Long-term complications of treatment and causes of mortality after Hodgkin's disease. Semin Radiat Oncol 1996;6:225-242.
35. Aleman BM, van den Belt-Dusebout AW, Klokman WJ, et al. Long-term cause-specific mortality of patients treated for Hodgkin's disease. J Clin Oncol 2003;21:3431-3439.
36. Sorensen K, Levitt GA, Bull C, et al. Late anthracycline cardiotoxicity after childhood cancer: a prospective longitudinal study. Cancer 2003;97:1991-1998.
37. Lipshultz SE, Lipsitz SR, Sallan SE, et al. Chronic progressive left ventricular systolic dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia. J Clin Oncol 2005;23:2629-2636.
38. Nysom K, Holm K, Lipsitz SR, et al. Relationship between cumulative anthracycline dose and late cardiotoxicity in childhood acute lymphoblastic leukemia. J Clin Oncol 1998;16:545-550.
39. Hequet O, Le QH, Moullet I, et al. Subclinical late cardiomyopathy after doxorubicin therapy for lymphoma in adults. J Clin Oncol 2004;22:1864-1871.
40. Mah K, Van Dyk J, Keane T, Poon PY. Acute radiation-induced pulmonary damage: a clinical study on the response to fractionated radiation therapy. Int J Radiat Oncol Biol Phys 1987;13:179-188.
41. Bossi G, Cerveri I, Volpini E, et al. Long-term pulmonary sequelae after treatment of childhood Hodgkin's disease. Ann Oncol 1997;8(suppl 1):19-24.
42. Fryer CJ, Hutchinson RJ, Krailo M, et al. Efficacy and toxicity of 12 courses of ABVD chemotherapy followed by low-dose regional radiation in advanced Hodgkin's disease in children: a report from the Children's Cancer Study Group. J Clin Oncol 1990;8:1971-1980.
43. Kreisman H, Wolkove N. Pulmonary toxicity of antineoplastic therapy. Semin Oncol 1992;19:508-520.
44. Mefferd JM, Donaldson SS, Link MP. Pediatric Hodgkin's disease: pulmonary, cardiac, and thyroid function following combined modality therapy. Int J Radiat Oncol Biol Phys 1989;16:679-685.
45. Horning SJ, Adhikari A, Rizk N, et al. Effect of treatment for Hodgkin's disease on pulmonary function: results of a prospective study. J Clin Oncol 1994;12:297-305.
46. Martin WG, Ristow KM, Habermann TM, et al. Bleomycin pulmonary toxicity has a negative impact on the outcome of patients with Hodgkin's lymphoma. J Clin Oncol 2005;23:7614-7620.
47. Gleeson HK, Darzy K, Shalet SM. Late endocrine, metabolic and skeletal sequelae following treatment of childhood cancer. Best Pract Res Clin Endocrinol Metab 2002;16:335-348.
48. Hancock SL, Cox RS, McDougall IR. Thyroid diseases after treatment of Hodgkin's disease. N Engl J Med 1991;325:599-605.
49. Constine LS, Donaldson SS, McDougall IR, et al. Thyroid dysfunction after radiotherapy in children with Hodgkin's disease. Cancer 1984;53:878-883.
50. Sklar C, Whitton J, Mertens A, et al. Abnormalities of the thyroid in survivors of Hodgkin's disease: data from the Childhood Cancer Survivor Study. J Clin Endocrinol Metab 2000;85:3227-3232.
51. Ben Arush MW, Solt I, Lightman A, et al. Male gonadal function in survivors of childhood Hodgkin and non-Hodgkin lymphoma. Pediatr Hematol Oncol 2000;17:239-245.
52. Gerres L, Bramswig JH, Schlegel W, et al. The effects of etoposide on testicular function in boys treated for Hodgkin's disease. Cancer 1998;83:2217-2222.
53. Hill M, Milan S, Cunningham D, et al. Evaluation of the efficacy of the VEEP regimen in adult Hodgkin's disease with assessment of gonadal and cardiac toxicity. J Clin Oncol 1995;13:387-395.
54. Kulkarni SS, Sastry PS, Saikia TK, et al. Gonadal function following ABVD therapy for Hodgkin's disease. Am J Clin Oncol 1997;20:354-357.
55. Kreuser ED, Felsenberg D, Behles C, et al. Long-term gonadal dysfunction and its impact on bone mineralization in patients following COPP/ABVD chemotherapy for Hodgkin's disease. Ann Oncol 1992;3(suppl 4):105-110.
56. Longo DL, Glatstein E, Duffey PL, et al. Alternating MOPP and ABVD chemotherapy plus mantle-field radiation therapy in patients with massive mediastinal Hodgkin's disease. J Clin Oncol 1997;15:3348-3346.
57. Howell SJ, Shalet SM. Effect of cancer therapy on pituitary-testicular axis. Int J Androl 2002;25:269-276.
58. Anselmo AP, Cartoni C, Bellantuono P, et al. Risk of infertility in patients with Hodgkin's disease treated with ABVD vs MOPP vs ABVD/MOPP. Haematologica 1990;75:155-158.
59. Relander T, Cavallin-Stahl E, Garwicz S, et al. Gonadal and sexual function in men treated for childhood cancer. Med Pediatr Oncol 2000;35:52-63.
60. Schellong G, Potter R, Bramswig J, et al. High cure rates and reduced long-term toxicity in pediatric Hodgkin's disease: the German-Austrian multicenter trial DAL-HD-90. The German-Austrian Pediatric Hodgkin's Disease Study Group. J Clin Oncol 1999;17:3736-3744.
61. Pedrick TJ, Hoppe RT. Recovery of spermatogenesis following pelvic irradiation for Hodgkin's disease. Int J Radiat Oncol Biol Phys 1986;12:117-121.
62. Izard M. Leydig cell function and radiation: a review of the literature. Radiother Oncol 1995;34:1-8.
63. Ash P. The influence of radiation on fertility in man. Br J Radiol 1980;53:271-278.
64. Lushbaugh CC, Casarett GW. The effects of gonadal irradiation in clinical radiation therapy: a review. Cancer 1976;37(suppl 2):1111-1125,
65. Bath LE, Wallace WH, Critchley HO. Late effects of the treatment of childhood cancer on the female reproductive system and the potential for fertility preservation. BJOG 2002;109:107-114.
66. Thomson AB, Critchley HO, Kelnar CJ, Wallace WH. Late reproductive sequelae following treatment of childhood cancer and options for fertility preservation. Best Pract Res Clin Endocrinol Metab 2002;16:311-334.
67. Damewood MD, Grochow LB. Prospects for fertility after chemotherapy or radiation for neoplastic disease. Fertil Steril 1986;45:443-459.
68. Byrne J, Infertility and premature menopause in childhood cancer survivors. Med Pediatr Oncol 1999;33:24-28.
69. Chiarelli AM, Marrett LD, Darlington G. Early menopause and infertility in females after treatment for childhood cancer diagnosed in 1964-1988 in Ontario, Canada. Am J Epidemiol 1999;150:245-254.
70. Hudson MM. Pediatric Hodgkin's therapy: time for a paradigm shift. J Clin Oncol 2002;20:3755-3757.
71. Linch DC, Gosden RG, Tulandi T, et al. Hodgkin's lymphoma: choice of therapy and late complications. Hematology (Am Soc Hematol Educ Program) 2000:205-221.
72. Schwartz CL. The management of Hodgkin disease in the young child. Curr Opin Pediatr 2003;15:10-16.
73. Horning SJ, Hoppe RT, Breslin S, et al. Stanford V and radiotherapy for locally extensive and advanced Hodgkin's disease: mature results of a prospective clinical trial. J Clin Oncol 2002;20:630-637.
74. Behringer K, Breuer K, Reineke T, et al. Secondary amenorrhea after Hodgkin's lymphoma is influenced by age at treatment, stage of disease, chemotherapy regimen, and the use of oral contraceptives during therapy: a report from the German Hodgkin's Lymphoma Study Group. J Clin Oncol 2005;23:7555-7564.
75. Haie-Meder C, Mlika-Cahanne N, Michel G, et al. Radiotherapy after ovarian transposition: ovarian function and fertility preservation. Int J Radiat Oncol Biol Phys 1993;25:419-424.
76. Ortin TT, Shostak CA, Donaldson SS. Gonadal status and reproductive function following treatment for Hodgkin's disease in childhood: the Stanford experience. Int J Radiat Oncol Biol Phys 1990;19:873-880.
77. Agarwal A. Semen banking in patients with cancer: 20-year experience. Int J Androl 2000;23(suppl 2):16-19.
78. Hallak J, Hendin B, Thomas A, Agarwal A. Investigation of fertilizing capacity of cryopreserved spermatogonia from patients with cancer. J Urol 1998;159:1217-1220.
79. Khalifa E, Oehninger S, Acosta A, et al. Successful fertilization and pregnancy outcome in in-vitro fertilization using cryopreserved/thawed spermatozoa from patients with malignant diseases. Hum Reprod 1992;7:105-108.
80. Muller J, Sonksen J, Sommer P, Schmiegelow M. Cryopreservation of semen from pubertal boys with cancer. Med Pediatr Oncol 2000;34:191-194.
81. Damani MN, Master V, Meng MV, et al. Postchemotherapy ejaculatory azoospermia: fatherhood with sperm from testis tissue with intracytoplasmic sperm injection. J Clin Oncol 2002;20:930-936.
82. Pfeifer S, Coutifaris C. Reproductive technologies 1998: options available for the cancer patient. Med Pediatr Oncol 1999;33:34-40.
83. Bahadur G, Steele S. Ovarian tissue cryopreservation for patients. Hum Reprod 1996;11:2215-2216.
84. Donnez J, Godin P, Qu J, Nisolle M. Gonadal cryopreservation in the young patient with gynaecological malignancy. Curr Opin Obstet Gynecol 2000;12:1-9.
85. Newton H. The cryopreservation of ovarian tissue as a strategy for preserving the fertility of cancer patients. Hum Reprod Update 1998;4:237-247.
86. Dudzinski DM. Ethical issues in fertility preservation for adolescent cancer survivors: oocyte and ovarian tissue cryopreservation. J Pediatr Adolesc Gynecol 2004;17:97-102.
87. Hansen M, Kurinczuk JJ, Bower C, Webb S. The risk of major birth defects after intracytoplasmic sperm injection and in vitro fertilization. N Engl J Med 2002;346:725-730.
88. Bonduelle M, Liebaers I, Deketelaere V, et al. Neonatal data on a cohort of 2889 infants born after ICSI (1991-1999) and of 2995 infants horn after IVF (1983-1999). Hum Reprod 2002;17:671-694.
89. Simpson JL, Lamb DJ. Genetic effects of intracytoplasmic sperm injection. Semin Reprod Med 2001;19:239-249.
90. Serafini P. Outcome and follow-up of children born after IVF-surrogacy. Hum Reprod Update 2001;7:23-27.
91. Ericson A, Kallen B. Congenital malformations in infants born after IVF: a population-based study. Hum Reprod 2001;16:504-509.
92. American Academy of Pediatrics. Immunocompromised children. In: Pickering LK, ed. Red Book: 2003 Report of the Committee on Infectious Diseases, 26th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2003:69-81.
93. Weiner MA, Landmann RG, DeParedes L, Leventhal BG. Vesiculated erythrocytes as a determination of splenic reticuloendothelial function in pediatric patients with Hodgkin's disease. J Pediatr Hematol Oncol 1995;17:338-341.
94. Zebrack BJ, Zeltzer LK, Whitton J, et al. Psychological outcomes in long-term survivors of childhood leukemia, Hodgkin's disease, and non-Hodgkin's lymphoma: a report from the Childhood Cancer Survivor Study. Pediatrics 2002;110(1 Pt 1):42-52.
95. Cuttini M, Da Fre M, Haupt R, et al. Survivors of childhood cancer: using siblings as a control group. Pediatrics 2003;112 (6 Pt 1):1454-1455; author reply 1454-1455.
96. Kornblith AB, Herndon JE 2nd, Zuckerman E, et al. Comparison of psychosocial adaptation of advanced stage Hodgkin's disease and acute leukemia survivors. Cancer and Leukemia Group B. Ann Oncol 1998;9:297-306.
97. Hjermstad MJ, Fossa SD, Oldervoll L, et al. Fatigue in long-term Hodgkin's disease survivors: a follow-up study. J Clin Oncol 2005;23:6587-6595.
98. Joly F, Henry-Amar M, Arveux P, et al. Late psychosocial sequelae in Hodgkin's disease survivors: a French population-based case-control study. J Clin Oncol 1996;14:2444-2453.
99. Mitby PA, Robison LL, Whitton JA, et al. Utilization of special education services and educational attainment among long-term survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. Cancer 2003;97:1115-1126.
100. Bowers DC, McNeil DE, Liu Y, et al. Stroke as a late treatment effect of Hodgkin's Disease: a report from the Childhood Cancer Survivor Study. J Clin Oncol 2005;23:6508-6515.
101. Megonigal MD, Cheung NK, Rappaport EF, et al. Detection of leukemia-associated MLL-GAS7 translocation early during chemotherapy with DNA topoisomerase II inhibitors. Proc Natl Acad Sci USA 2000;97:2814-2819.
102. National Institute for Clinical Excellence (NICE). Service guidance for improving outcomes in children and young people with cancer. Accessed 1/10/05. Available at: http://www.nice.org.uk.
103. Scottish Intercollegiate Guidelines Network (SIGN). Long term follow up of survivors of childhood cancer. A national clinical guideline. Accessed 1/10/05. Available at: http://www.sign.ac.uk.
104. United Kingdom Children's Cancer Study Group. UKCCSG homepage. Accessed 1/10/05. Available at: http://www.ukccsg.org.
105. Landier W, Bhatia S, Eshelman DA, et al. Development of risk-based guidelines for pediatric cancer survivors: the Children's Oncology Group Long-Term Follow-Up Guidelines from the Children's Oncology Group Late Effects Committee and Nursing Discipline. J Clin Oncol 2004;22:4979-4990.
106. Rubin P, Constine LS, Fajardo LF, et al. RTOG Late Effects Working Group. Overview. Late Effects of Normal Tissues (LENT) scoring system. Int J Radiat Oncol Biol Phys 1995;31:1041-1042.